Switch theme
Sign up to access all valuation multiples
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.
2017
331
LTM Revenue $3.3M
LTM EBITDA -$263M
$118M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Replimune Group has a last 12-month revenue of $3.3M and a last 12-month EBITDA of -$263M.
In the most recent fiscal year, Replimune Group achieved revenue of n/a and an EBITDA of -$206M.
Replimune Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Replimune Group valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$167M | -$206M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$118M | -$174M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Replimune Group's stock price is $8.
Replimune Group has current market cap of $578M, and EV of $118M.
See Replimune Group trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $118M | $578M | XXX | XXX | XXX | XXX | $-2.86 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Replimune Group has market cap of $578M and EV of $118M.
Replimune Group's trades at 36.1x LTM EV/Revenue multiple, and -0.4x LTM EBITDA.
Analysts estimate Replimune Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Replimune Group and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $118M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -0.5x | XXX | XXX | XXX |
| P/E | -2.5x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -0.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpReplimune Group's NTM/LTM revenue growth is 1244%
Replimune Group's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.7M for the same period.
Over next 12 months, Replimune Group's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Replimune Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Replimune Group and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | 23% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.7M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Replimune Group acquired XXX companies to date.
Last acquisition by Replimune Group was XXXXXXXX, XXXXX XXXXX XXXXXX . Replimune Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Replimune Group founded? | Replimune Group was founded in 2017. |
| Where is Replimune Group headquartered? | Replimune Group is headquartered in United States of America. |
| How many employees does Replimune Group have? | As of today, Replimune Group has 331 employees. |
| Who is the CEO of Replimune Group? | Replimune Group's CEO is Dr. Sushil Patel, PhD. |
| Is Replimune Group publicy listed? | Yes, Replimune Group is a public company listed on NAS. |
| What is the stock symbol of Replimune Group? | Replimune Group trades under REPL ticker. |
| When did Replimune Group go public? | Replimune Group went public in 2018. |
| Who are competitors of Replimune Group? | Similar companies to Replimune Group include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Replimune Group? | Replimune Group's current market cap is $578M |
| What is the current revenue of Replimune Group? | Replimune Group's last 12-month revenue is $3.3M. |
| What is the current EBITDA of Replimune Group? | Replimune Group's last 12-month EBITDA is -$263M. |
| What is the current EV/Revenue multiple of Replimune Group? | Current revenue multiple of Replimune Group is 36.1x. |
| What is the current EV/EBITDA multiple of Replimune Group? | Current EBITDA multiple of Replimune Group is -0.4x. |
| Is Replimune Group profitable? | Yes, Replimune Group is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
